Ospemifeen verbeterde de postmenopauzale fysiologische veranderingen.
CYP3A4 are involved in the metabolism of ospemifene.
CYP3A4 zijn betrokken bij de metabolisatie van ospemifeen.
It is unknown if ospemifene is a substrate for BCRP in the intestine.
Het is onbekend of ospemifeen een substraat is voor het BCRP in de ingewanden.
The risk of cerebrovascular events associated with ospemifene cannot be excluded.
Het risico op cerebrovasculaire voorvallen die verband houden met ospemifeen kan niet uitgesloten worden.
In in-vitro studies ospemifene is a weak inhibitor for CYP2B6,
In in-vitro- onderzoeken is ospemifeen een zwakke remmer van CYP2B6,
Therefore, caution is recommended when ospemifene is combined with orlistat.
Daarom is voorzichtigheid geboden wanneer ospemifeen met orlistat wordt gecombineerd.
Ospemifene exhibits linear pharmacokinetics in the fed state within the dose range of 60 mg to 240 mg.
Ospemifeen vertoont lineaire farmacokinetiek in de niet-nuchtere toestand binnen het dosisbereik van 60 mg tot 240 mg.
Therefore care should be taken if ospemifene is administered with a BCRP inhibitor.
Daarom is voorzichtigheid geboden wanneer ospemifeen met een BCRP-remmer wordt toegediend.
In the liver, an increase in hepatocellular tumours were recorded at all ospemifene dose levels.
In de lever werd bij alle dosisniveaus van ospemifeen een verhoogd aantal hepatocellulaire tumoren vastgesteld.
If pregnancy occurs during treatment with ospemifene, ospemifene should be withdrawn immediately.
Indien tijdens behandeling met ospemifeen een zwangerschap optreedt, dient onmiddellijk met ospemifeen te worden gestopt.
In vitro, ospemifene and 4-hydroxyospemifene inhibited glucuronidation via UGT1A3
In vitro remden ospemifeen en 4-hydroxyospemifeen de glucuronidatie via UGT1A3
If necessary, because of impaired tolerance, ospemifene should be stopped as long as treatment with fluconazole lasts.
Vanwege verminderde tolerantie moet indien nodig met ospemifeen worden gestopt zolang de behandeling met fluconazol duurt.
In vitro, ospemifene and 4-hydroxyospemifene did not inhibit or induce the activity of CYP450 enzymes at clinically relevant concentrations.
In vitro remden of induceerden ospemifeen en 4-hydroxyospemifeen de activiteit van CYP450- enzymen in klinisch relevante concentraties niet.
There is therefore no reason to expect that strong CYP3A4 inhibitors would cause a clinically meaningful change in ospemifene exposure.
Er is derhalve geen reden om aan te nemen dat krachtige CYP3A4-remmers klinisch relevante veranderingen in de blootstelling aan ospemifeen zullen veroorzaken.
No clinically meaningful differences in ospemifene pharmacokinetics have been observed over the age range studied(40-80) years of age.
Er zijn geen klinisch relevante verschillen in de farmacokinetiek van ospemifeen waargenomen tussen de leeftijden in de onderzochte leeftijdscategorie 40-80.
Mean ospemifene Cmax and AUC0-24hr were 785 ng/mL
De gemiddelde Cmax en AUC0-24u van ospemifeen waren respectievelijk 785 ng/ml
There was a single subject(0.3%) who developed endometrial hyperplasia in the ospemifene group(simple hyperplasia without atypia) 88 days after the last dose of study drug.
Eén enkele proefpersoon(0,3%) in de ospemifeengroep kreeg 88 dagen na de laatste dosis van het onderzoeksgeneesmiddel endometriumhyperplasie eenvoudige hyperplasie zonder atypie.
Uitslagen: 81,
Tijd: 0.0373
Hoe "ospemifene" te gebruiken in een Engels zin
Christoph switchable and pull-in ospemifene generic cialis illuminates its reverberation or emancipation extensively.
You should take ospemifene with a meal, preferably at the same time each day.
The onset of acne can ospemifene mechanism of action happen at numerous levels in life.
Ospemifene improves vaginal pH, vaginal maturation index, and dyspareunia due to vulvovaginal atrophy in postmenopausal women.
Adverse effects of ospemifene include hot flashes, vaginal discharge, muscle spasms, genital discharge, and excessive sweating.
Let your doctor know if ospemifene becomes less effective or is no longer controlling your symptoms.
Ospemifene is a selective estrogen receptor modulator that can be used as an alternative to vaginal estrogen.
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence.
Cellulite troubles could be dealt ospemifene mechanism of action with by using grapefruit, tangerine or orange oil.
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.
English
Deutsch
Español
Français
عربى
Български
বাংলা
Český
Dansk
Ελληνικά
Suomi
עִברִית
हिंदी
Hrvatski
Magyar
Bahasa indonesia
Italiano
日本語
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Norsk
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt
中文